Literature DB >> 11100053

Pathologic evaluation of sentinel lymph nodes in colorectal carcinoma.

D A Wiese1, S Saha, J Badin, P S Ng, J Gauthier, A Ahsan, L Yu.   

Abstract

BACKGROUND: The identification of lymph node metastases in colorectal resection specimens is necessary for accurate tumor staging. However, routine lymph node dissection by the pathologist yields only a subset of nodes removed surgically and may not include those nodes most directly in the path of lymphatic drainage from the tumor. Intraoperative mapping of such sentinel lymph nodes (SLNs) has been reported in cases of melanoma and breast cancer. We applied a similar method to cases of colorectal carcinoma, with emphasis on the pathology of the SLNs.
METHODS: Eighty-three consecutive patients with colorectal carcinoma were evaluated after intraoperative injection of 1 to 2 mL of 1% isosulfan blue dye (Lymphazurin) into the peritumoral subserosa. Blue-stained lymph nodes were suture-tagged by the surgeon within minutes of the injection for identification by the pathologist, and a standard resection was performed. Designated SLNs were sectioned at 10 levels through the block; a cytokeratin immunostain (AE1) was also obtained. To evaluate the possibility that increased detection of metastases in the SLN might be solely due to increased histologic sampling, all initially negative non-SLNs in the first 25 cases were sectioned also at 10 levels.
RESULTS: Sentinel lymph nodes were identified intraoperatively in 82 (99%) of 83 patients and accounted for 152 (11.9%) of 1275 lymph nodes recovered, with an average of 1.9 SLNs per patient. A total of 99 positive lymph nodes (38 positive SLNs and 61 positive non-SLNs) were identified in 34 node-positive patients. The SLNs were the only site of metastasis in 17 patients (50%), while 14 patients (41%) had both positive SLNs and non-SLNs. Three patients (9%) had positive non-SLNs with negative SLNs, representing skip metastases. In patients with positive SLNs, 91 (19%) of 474 total lymph nodes and 53 (12%) of 436 non-SLNs were positive for metastasis. In patients with negative SLNs, 8 (1%) of 801 total lymph nodes and 8 (1.2%) of 687 non-SLNs were positive for metastasis. Multilevel sections of 330 initially negative non-SLNs in the first 25 patients yielded only 2 additional positive nodes (0. 6%). All patients with positive SLNs were correctly staged by a combination of 4 representative levels through the SLN(s) together with a single cytokeratin immunostain.
CONCLUSIONS: Intraoperative mapping of SLNs in colorectal carcinoma identifies lymph nodes likely to contain metastases. Focused pathologic evaluation of the 1 to 4 SLNs so identified can improve the accuracy of pathologic staging.

Entities:  

Mesh:

Year:  2000        PMID: 11100053     DOI: 10.5858/2000-124-1759-PEOSLN

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  16 in total

1.  One hundred consecutive cases of sentinel lymph node mapping in early colorectal carcinoma: detection of missed micrometastases.

Authors:  Thomas F Wood; Dean T Nora; Donald L Morton; Roderick R Turner; Decio Rangel; William Hutchinson; Anton J Bilchik
Journal:  J Gastrointest Surg       Date:  2002 May-Jun       Impact factor: 3.452

Review 2.  Nodal staging of colorectal carcinomas and sentinel nodes.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

3.  Extended lymphadenectomy in colon cancer is debatable.

Authors:  Jamie Murphy; Tonia Young-Fadok
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

4.  Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas.

Authors:  Piotr Nowaczyk; Dawid Murawa; Karol Połom; Magdalena Waszyk-Nowaczyk; Arkadiusz Spychała; Michał Michalak; Paweł Murawa
Journal:  Langenbecks Arch Surg       Date:  2012-03-14       Impact factor: 3.445

Review 5.  Challenging the conventional treatment of colon cancer by sentinel lymph node mapping and its role of detecting micrometastases for adjuvant chemotherapy.

Authors:  Sukamal Saha; Mohamed Elgamal; Meghan Cherry; Robin Buttar; Swetha Pentapati; Suresh Mukkamala; Kiran Devisetty; Sunil Kaushal; Mustafa Alnounou; Trevor Singh; Sandeep Grewal; David Eilender; Madan Arora; David Wiese
Journal:  Clin Exp Metastasis       Date:  2018-08-16       Impact factor: 5.150

6.  One hundred consecutive cases of sentinel lymph node mapping in colon cancer-the results of prospective, single--centre feasibility study with implementation of immunohistochemical staining.

Authors:  Dawid Murawa; Piotr Nowaczyk; Michael Hünerbein; Karol Połom; Violetta Filas; Jan Bręborowicz; Paweł Murawa
Journal:  Int J Colorectal Dis       Date:  2011-03-16       Impact factor: 2.571

Review 7.  Epidemiology and management options for colorectal cancer in children.

Authors:  Raya Saab; Wayne L Furman
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  [Optimization of staging in colon cancer using sentinel lymph node biopsy].

Authors:  A Bembenek; U Schneider; S Gretschel; C Ulmer; P M Schlag
Journal:  Chirurg       Date:  2005-01       Impact factor: 0.955

9.  Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01.

Authors:  Alexander Stojadinovic; Aviram Nissan; Mladjan Protic; Carol F Adair; Diana Prus; Slavica Usaj; Robin S Howard; Dragan Radovanovic; Milan Breberina; Craig D Shriver; Ronit Grinbaum; Jeffery M Nelson; Tommy A Brown; Herbert R Freund; John F Potter; Tamar Peretz; George E Peoples
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

10.  Lymph node harvests directly influence the staging of colorectal cancer: evidence from a regional audit.

Authors:  D F H Pheby; D F Levine; R W Pitcher; N A Shepherd
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.